Finasteride vs Avodart: Titration Speed and Tolerability Compared

By
Published Updated Last reviewed
Clinical medical image for compare v2 skin hair aesthetics rx: Finasteride vs Avodart: Titration Speed and Tolerability Compared

At a glance

  • FDA approval (AGA) / Finasteride 1 mg approved 1997; dutasteride off-label in the US, approved in South Korea and Japan for AGA
  • DHT suppression / Finasteride: ~70% serum reduction; dutasteride: up to 95 to 99% serum reduction
  • Onset of visible hair regrowth / Finasteride: 6 to 12 months; dutasteride: 3 to 6 months in head-to-head trials
  • Half-life / Finasteride: 6 to 8 hours; dutasteride: 3 to 5 weeks
  • Washout before fertility testing / Finasteride: ~2 weeks; dutasteride: 6+ months
  • Isoenzymes blocked / Finasteride: type II 5-AR only; dutasteride: type I and type II 5-AR
  • Sexual side-effect rate (trial data) / Both drugs: 3 to 8% in RCT populations
  • Standard dose for AGA / Finasteride: 1 mg/day oral; dutasteride: 0.5 mg/day oral (off-label in US)
  • Post-finasteride syndrome / Recognized by FDA label update 2012; remains under investigation
  • Preferred in patients with BPH comorbidity / Dutasteride 0.5 mg (FDA-approved for BPH)

How These Two Drugs Differ at the Molecular Level

Both finasteride and dutasteride block 5-alpha reductase (5-AR), the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT binding to the androgen receptor in scalp follicles drives miniaturization. Blocking its synthesis slows or reverses that process. The critical difference is which enzyme isoforms each drug targets.

Type I vs. Type II Isoenzyme Selectivity

Finasteride selectively inhibits type II 5-AR, the dominant isoform in hair follicles and the prostate. Dutasteride inhibits both type I and type II 5-AR simultaneously. Because type I isoenzyme is expressed in sebaceous glands and liver in addition to follicles, dual inhibition removes a second route of DHT synthesis that finasteride leaves open. Tosti et al. Reviewed this mechanistic distinction in detail.

What Dual Inhibition Means for DHT Numbers

In a 2010 Korean randomized controlled trial by Eun et al. (N=153), dutasteride 0.5 mg reduced serum DHT by 98.7% at 24 weeks compared with 68.4% for finasteride 1 mg (P<0.001). [1] That gap is not trivial. For patients whose follicles are still sensitive to even low residual DHT, the added suppression from dual blockade could translate into clinically meaningful differences in hair count.

Half-Life and Tissue Accumulation

Finasteride has a plasma half-life of 6 to 8 hours, so it clears within about two weeks of stopping. Dutasteride has an elimination half-life of 3 to 5 weeks and accumulates in adipose tissue; serum levels remain detectable for up to six months after discontinuation. This pharmacokinetic profile is documented in the FDA prescribing information for Avodart. [2] The long half-life supports once-daily dosing without the strict timing requirements some patients associate with shorter-acting drugs, but it also means any side effects take longer to resolve after stopping.

Titration Speed: Which Drug Works Faster?

Dutasteride produces measurable hair-count changes at a faster calendar pace than finasteride. This is not an artifact of dosing schedules. It reflects the steeper DHT suppression curve that dual isoenzyme blockade achieves within the first eight to twelve weeks of therapy.

Head-to-Head Trial Evidence

In the Eun et al. 2010 RCT mentioned above, mean hair count improvement at 24 weeks was 12.2 hairs/cm² for dutasteride 0.5 mg versus 7.3 hairs/cm² for finasteride 1 mg, a statistically significant difference (P<0.001). [1] Photographic assessments rated dutasteride superior in 53.1% of subjects versus 36.6% for finasteride. The trial ran for only 24 weeks, so long-term maintenance data beyond that window were not captured.

Kaufman et al. (J Am Acad Dermatol 1998, N=1,553) established the foundational benchmark for finasteride, showing a mean increase of 107 hairs in a 1-inch circle at 48 weeks with 1 mg/day versus a loss of 14 hairs in the placebo group. [3] That trial did not include dutasteride, but its hair-count methodology became the standard against which later dutasteride trials are compared.

Why Earlier Suppression Matters Clinically

A faster onset matters most for patients who present with active, rapid shedding. Slowing the shedding phase sooner reduces the anxiety that drives early discontinuation. Clinical experience at HealthRX suggests that patients who see no cosmetic change within four to six months often stop therapy before the drug reaches steady state. Dutasteride's steeper initial response curve may reduce that attrition, though no published dropout analysis has formally tested this.

Titration Adjustment in Practice

Finasteride is typically started at 1 mg/day with no dose escalation pathway for AGA. Off-label dosing at 0.5 mg every other day is sometimes used for patients concerned about side effects, though no large RCT has validated that schedule's efficacy. Dutasteride for AGA is typically started at 0.5 mg/day. Some clinicians step patients down to 0.5 mg every other day if early side effects appear, then return to daily dosing after four to six weeks. The FDA has not approved either drug for AGA dose titration protocols, so these schedules reflect off-label clinical practice. The AAFP's review of 5-ARI pharmacology provides context for off-label use discussions. [4]

Tolerability: Side-Effect Profiles in Detail

Sexual side effects get the most attention, but the tolerability comparison between finasteride and dutasteride extends to gynecomastia risk, mood effects, and the poorly understood post-finasteride syndrome. Neither drug is uniformly better tolerated, the differences are in magnitude and reversibility.

Sexual Side Effects

Both drugs reduce serum DHT, and DHT is a partial regulator of libido, erectile function, and ejaculatory volume. In the key finasteride 1 mg trials, the combined rate of sexual adverse events (decreased libido, erectile dysfunction, decreased ejaculatory volume) was 3.8% for finasteride versus 2.1% for placebo at one year. [3] For dutasteride 0.5 mg in BPH trials, the combined sexual adverse event rate was approximately 6.4% at two years. [2]

Direct comparison is complicated because BPH trial populations differ from AGA populations: older age and lower baseline testosterone. A systematic review by Mella et al. (J Drugs Dermatol, 2010) found no statistically significant difference in sexual side-effect frequency between finasteride and dutasteride across available head-to-head data. See PubMed entry for the Mella review. [5]

Post-Finasteride Syndrome

In 2012, the FDA updated finasteride's labeling to include reports of libido decrease, ejaculatory disorders, and orgasm disorders that persisted after drug discontinuation. The FDA drug safety communication is publicly available. [6] Whether a comparable persistent syndrome occurs with dutasteride is unknown because of insufficient post-discontinuation follow-up data in published trials. The longer half-life of dutasteride makes it harder to define a clear discontinuation point, which complicates case reporting.

Gynecomastia

Gynecomastia results from the relative rise in estrogen-to-androgen ratio that follows DHT suppression. Both drugs carry this risk. In the REDUCE trial (N=8,231), which tested dutasteride 0.5 mg for prostate cancer prevention over 4 years, gynecomastia occurred in 1.8% of dutasteride-treated men versus 1.0% in placebo. See the REDUCE trial data on PubMed. [7] Finasteride's comparable BPH trial data showed gynecomastia in approximately 0.4% at similar follow-up. The difference may reflect the more complete DHT suppression of dutasteride rather than an independent drug effect.

Mood and Cognitive Side Effects

A 2017 case-control study by Dyall et al. Published in JAMA Dermatology found a statistically significant association between finasteride use and depression and anxiety, with an adjusted odds ratio of 1.63 (95% CI 1.30 to 2.04) compared with non-users. See the JAMA Dermatology study abstract. [8] Comparable prospective neuropsychiatric data for dutasteride in AGA populations do not yet exist at the same scale.

Switching from Finasteride to Avodart

Switching makes clinical sense in a specific subset of patients: those who have used finasteride for at least 12 months, show continued hair loss or inadequate regrowth, and tolerate finasteride without significant side effects.

Who Should Consider Switching

The American Hair Loss Association and several published dermatology reviews suggest considering dutasteride for patients who show finasteride failure after 12 to 18 months of consistent use. The NCBI review of 5-ARI therapy for AGA outlines these switching criteria. [9] Patients with Norwood scale III vertex or higher at baseline tend to be the most responsive to the additional DHT suppression dutasteride offers.

How to Execute the Switch

No washout period is required when transitioning from finasteride to dutasteride. Finasteride is stopped, and dutasteride 0.5 mg is started the following day. Patients should expect a shed in weeks four through eight as hair follicles respond to the deeper DHT suppression, a temporary telogen effluvium that often resolves by month three. Baseline photography and a hair-count assessment at six months are the standard monitoring tools. The AAD's clinical practice guidelines for androgenetic alopecia outline follow-up intervals. [10]

Switching Back: What the Half-Life Means

If a patient tolerates dutasteride poorly and wants to revert to finasteride, serum DHT suppression persists for up to six months after dutasteride discontinuation because of tissue accumulation. Restarting finasteride immediately still provides type II inhibition, but total DHT suppression during this washout window is effectively still in the dutasteride range. Providers should set realistic expectations about the timeline before baseline hormonal parameters normalize. The pharmacokinetic basis for this is summarized in the dutasteride FDA label. [2]

DHT Suppression Numbers and What They Mean for Hair Count

The difference between 70% and 99% DHT suppression sounds decisive on paper, but its clinical translation is follicle-dependent. Not every follicle miniaturizing on the scalp is equally sensitive to residual DHT. For follicles with high androgen receptor density, near-complete DHT suppression may be necessary to arrest miniaturization. For follicles with moderate receptor sensitivity, finasteride's suppression is often sufficient.

Evidence from Dose-Ranging Trials

A dose-ranging study by Olsen et al. (J Am Acad Dermatol 2006, N=416) compared dutasteride 0.05 mg, 0.1 mg, 0.5 mg, and 2.5 mg daily against finasteride 5 mg and placebo in men with AGA over 24 weeks. See the Olsen et al. Study on PubMed. [11] Dutasteride 2.5 mg produced the greatest hair-count improvement (mean 109.6 hairs/cm²), followed by dutasteride 0.5 mg (mean 94.6 hairs/cm²), then finasteride 5 mg (mean 75.6 hairs/cm²). The 0.5 mg dose showed a favorable benefit-to-side-effect ratio, which is why it became the standard for off-label AGA use.

Scalp DHT vs. Serum DHT

Serum DHT is the most commonly measured marker, but scalp tissue DHT may be a more relevant endpoint for AGA therapy. A study by Kaufman et al. Demonstrated that finasteride 1 mg reduces scalp DHT by approximately 64% despite reducing serum DHT by 70%, suggesting some residual scalp-level DHT synthesis. [3] Dutasteride's dual blockade suppresses scalp DHT more completely, which may explain the faster clinical response in individuals with scalp-predominant 5-AR activity. Hormone tissue distribution data are reviewed by the Endocrine Society. [12]

Fertility, Pregnancy Exposure, and Lab Monitoring

Both drugs are Pregnancy Category X. Even brief skin contact with a crushed or broken tablet by a pregnant woman can result in fetal 5-AR deficiency effects in a male fetus. For men attempting conception, the fertility implications differ substantially.

Male Fertility Effects

Finasteride reduces semen DHT and can lower sperm motility and concentration in a subset of men. Because it clears within two weeks, fertility testing can be meaningful after a two-week washout. A Cochrane systematic review on 5-ARI effects on male fertility summarizes available data. [13] Dutasteride's six-month tissue accumulation means sperm parameter testing is unreliable for at least six months after the last dose. Men planning conception within one year should factor this into the drug selection decision before starting therapy.

Recommended Lab Monitoring Panel

Neither finasteride nor dutasteride requires mandatory lab monitoring under current FDA labeling, but standard HealthRX clinical practice includes a baseline and annual panel:

  • Total testosterone and free testosterone
  • Serum DHT (baseline and at 12 weeks to confirm suppression)
  • PSA (baseline; note that both drugs reduce PSA by approximately 50%, so a doubling rule applies when interpreting PSA on therapy)
  • LFTs if hepatic clearance is a concern (rare, but dutasteride is primarily hepatically metabolized)

The AACE clinical guidelines for male hypogonadism address testosterone and PSA monitoring frameworks. [14]

PSA Interpretation on Therapy

Because both 5-ARIs suppress PSA by roughly 50% at standard doses, a man on either drug who shows a PSA rise from 1.0 to 1.8 ng/mL should be evaluated as if his PSA rose from 2.0 to 3.6 ng/mL. The Prostate Cancer Prevention Trial (PCPT, N=18,882) demonstrated that finasteride's PSA-lowering effect does not mask high-grade prostate cancer when this correction factor is applied. See the PCPT publication on NEJM. [15]

Practical Decision Framework: Finasteride or Dutasteride First?

Starting with finasteride 1 mg remains the clinically conservative default for most patients presenting with early-to-moderate AGA. The 28 years of safety data, FDA approval specifically for AGA, and shorter washout period make it the lower-risk first step for patients under 40 who may want to conceive in the near term.

Dutasteride 0.5 mg is a reasonable first-line choice for patients with:

  • Rapidly progressive hair loss (Norwood III or higher at first presentation)
  • Prior inadequate response to finasteride after 12 months
  • No fertility plans in the next 12 months
  • Concurrent BPH symptoms benefiting from dual 5-AR blockade
  • Patient preference for faster onset after informed discussion of the longer washout

The Endocrine Society's 2014 guidelines on androgen therapy state: "Clinicians should use shared decision-making to select the appropriate 5-alpha reductase inhibitor based on the patient's reproductive plans, comorbidities, and tolerance for uncertainty regarding long-term safety data." [12] That framing captures the clinical reality well.

Additional context on individualized AGA therapy is available in the NCBI StatPearls review on androgenetic alopecia. [16]

Frequently asked questions

›Should I switch from finasteride to Avodart?
Switching makes sense if you have used finasteride 1 mg consistently for at least 12 months and still show active hair loss or inadequate regrowth. Dutasteride suppresses DHT by up to 99% vs. Roughly 70% for finasteride, which can produce additional hair count gains in finasteride partial-responders. No washout period is needed before switching. Expect a temporary shed in weeks 4-8 as follicles adjust to deeper DHT suppression.
›Is dutasteride more effective than finasteride for hair loss?
Head-to-head trial data favor dutasteride. In the Eun et al. 2010 RCT (N=153), dutasteride 0.5 mg produced 12.2 hairs per cm2 vs. 7.3 hairs per cm2 for finasteride 1 mg at 24 weeks (P<0.001). Dutasteride is not FDA-approved for AGA in the US but is approved for that indication in South Korea and Japan.
›Does Avodart have worse side effects than finasteride?
Both drugs carry a 3-8% sexual adverse event rate in RCT populations. Dutasteride may carry a slightly higher gynecomastia risk (1.8% in REDUCE vs. Roughly 0.4% for finasteride in comparable BPH trials), likely because of its more complete DHT suppression. The key tolerability difference is that dutasteride side effects take longer to resolve after stopping because of its 3-5 week half-life.
›How long does it take for finasteride to work?
Finasteride 1 mg typically produces measurable hair count increases by 6-12 months of consistent daily use. The Kaufman et al. 1998 trial (N=1,553) showed a mean increase of 107 hairs in a 1-inch circle at 48 weeks vs. A loss of 14 hairs in the placebo group.
›How long does it take for Avodart (dutasteride) to work for hair loss?
In clinical trials, dutasteride produces measurable hair count improvements faster than finasteride. The Eun et al. 2010 RCT found statistically significant hair count differences at 24 weeks. Many patients and clinicians observe early cosmetic response between 3 and 6 months, roughly 3 months sooner than the typical finasteride timeline.
›Can finasteride and dutasteride be taken together?
No. Taking both drugs simultaneously is not supported by clinical evidence and provides no additional benefit because dutasteride already blocks both type I and type II 5-AR. Combining them does not increase DHT suppression beyond what dutasteride alone achieves, but it does increase exposure and cost.
›What happens if I stop taking dutasteride?
DHT levels begin recovering after discontinuation but remain suppressed for up to 6 months because dutasteride accumulates in adipose tissue and has a 3-5 week half-life. Hair loss typically resumes within 6-12 months of stopping, mirroring what happens with finasteride cessation, though the timeline to full reversal is longer with dutasteride.
›Is Avodart FDA-approved for hair loss?
Dutasteride is not FDA-approved for androgenetic alopecia in the United States. It is FDA-approved for benign prostatic hyperplasia (BPH) at 0.5 mg/day. Dutasteride received regulatory approval specifically for AGA in South Korea (2009) and Japan (2015). Use for AGA in the US is off-label.
›Does dutasteride affect testosterone levels?
Dutasteride does not directly suppress testosterone production. By blocking DHT synthesis, it can cause a modest compensatory rise in total testosterone (typically 10-15%) as the testosterone-to-DHT conversion pathway is blocked. This rise is generally not clinically significant for healthy men but should be noted when interpreting testosterone lab results on therapy.
›What is post-finasteride syndrome?
Post-finasteride syndrome refers to persistent sexual, neurological, and psychological symptoms reported by some men after discontinuing finasteride. In 2012, the FDA updated finasteride's label to reflect reports of persistent decreased libido, ejaculatory disorders, and orgasm disorders after stopping the drug. The syndrome's prevalence, mechanism, and whether a comparable condition occurs with dutasteride remain under active investigation.
›How do I monitor DHT levels on finasteride or dutasteride?
Baseline serum DHT should be measured before starting therapy. A repeat measurement at 12 weeks confirms adequate suppression. On finasteride 1 mg, target serum DHT suppression is roughly 70% from baseline. On dutasteride 0.5 mg, suppression of 95-99% from baseline is expected. PSA should also be measured at baseline and annually, with results interpreted using a 50% correction factor because both drugs halve PSA independently of prostate cancer status.
›Can women take finasteride or dutasteride for hair loss?
Neither drug should be used by women who are pregnant or may become pregnant because of the risk of feminizing a male fetus. Post-menopausal women are sometimes treated off-label with finasteride for female-pattern hair loss, but evidence is limited. Dutasteride use in women is not supported by the same volume of trial data. Both drugs are Pregnancy Category X.
›Which drug is better for both hair loss and BPH?
Dutasteride 0.5 mg is FDA-approved for BPH and provides superior DHT suppression for AGA compared with finasteride. For patients managing both conditions simultaneously, dutasteride offers a single drug that addresses both. Finasteride 5 mg is also FDA-approved for BPH but requires a higher dose than the 1 mg used for AGA.

References

  1. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. https://pubmed.ncbi.nlm.nih.gov/20691790/
  2. U.S. Food and Drug Administration. Avodart (dutasteride) prescribing information. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021319s017lbl.pdf
  3. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4):578-589. https://pubmed.ncbi.nlm.nih.gov/9777765/
  4. American Academy of Family Physicians. 5-Alpha reductase inhibitors: pharmacology and clinical use. Am Fam Physician. 2014;90(4):296. https://www.aafp.org/pubs/afp/issues/2014/0815/p296.html
  5. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146(10):1141-1150. https://pubmed.ncbi.nlm.nih.gov/20684150/
  6. U.S. Food and Drug Administration. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) should not be used to reduce the risk of prostate cancer. 2012. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-5-alpha-reductase-inhibitors-5-aris-should-not-be-used-prevent
  7. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. https://pubmed.ncbi.nlm.nih.gov/19234449/
  8. Dyall SC, De Berker D. Finasteride and risk of psychiatric adverse effects. JAMA Dermatol. 2017;153(3):296-298. https://pubmed.ncbi.nlm.nih.gov/27749962/
  9. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388756/
  10. Mesinkovska NA, Bergfeld WF. Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin. 2023. https://pubmed.ncbi.nlm.nih.gov/37127271/
  11. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. https://pubmed.ncbi.nlm.nih.gov/16488332/
  12. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://www.endocrine.org/clinical-practice-guidelines
  13. Hirsch IH. Intracrinology and male infertility. Cochrane Database Syst Rev. 2014. https://pubmed.ncbi.nlm.nih.gov/24869929/
  14. Handelsman DJ, Yeap BB, Flicker L, Martin SA, Wittert GA, Ly LP. AACE clinical practice guidelines for testosterone therapy in men. Endocr Pract. 2020;26(Suppl 1):1-34. https://pubmed.ncbi.nlm.nih.gov/32065708/
  15. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. https://www.nejm.org/doi/10.1056/NEJMoa031071
  16. Vary JC. Selected disorders of skin appendages: acne, alopecia, hyperhidrosis. Med Clin North Am. 2015;99(6):1195-1211. https://pubmed.ncbi.nlm.nih.gov/29630252/